No Data
No Data
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business de
NovAccess Global Jumps on Announcing $10.7 Million Financing
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit.Event:December 7th In
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app
NovAccess Global Partners With BCN Biosciences to Expand Immunotherapy Platform
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS TumorsPotential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology MarketCLEVELAND, OH /
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executiv
No Data